Results 161 to 170 of about 1,098,652 (240)

A New ICD-10 Code for Hemorrhagic Myocardial Infarction. [PDF]

open access: yesJACC Adv
Kalra A, Kumbhani DJ, Dharmakumar R.
europepmc   +1 more source

Performance of the Predicting Risk of Cardiovascular Disease Events Calculator in Rheumatoid Arthritis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Evaluate performance of the Predicting Risk of Cardiovascular Disease Events (PREVENT) calculator in rheumatoid arthritis (RA). Methods Patients with RA were matched up to 10 controls on age, sex, and enrollment year using National Veterans Health Administration, Medicare, and National Death Index data (2006–2020).
Tate M. Johnson   +13 more
wiley   +1 more source

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie   +12 more
wiley   +1 more source

Hematological parameters as predictors of complex angiographic coronary lesions in patients with acute myocardial infarction. [PDF]

open access: yesPLoS One
Ramos TMB   +7 more
europepmc   +1 more source

A Metabolomic Signature Predicts Gout Flare Clinical Outcome Associated With Colchicine Prophylaxis

open access: yesArthritis &Rheumatology, EarlyView.
Objective This study investigated that serum metabolomics, before urate‐lowering therapy (ULT) initiation, could serve as a biomarker for responsiveness to colchicine prophylaxis in patients with gout commencing treat‐to‐target ULT. Methods We studied a multicenter prospective cohort (n = 409) initiating treat‐to‐target ULT plus colchicine prophylaxis.
Wenyan Sun   +13 more
wiley   +1 more source

Machine Learning to Predict Remission Between Six and 24 Months in Rheumatoid Arthritis: Insights from the JAK‐pot Collaboration

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To develop, externally validate, and simplify a machine‐learning (ML) model to predict remission between six and 24 months in rheumatoid arthritis (RA) patients initiating TNF inhibitors, JAK inhibitors, IL‐6 inhibitors, abatacept, or rituximab, using data from 11 international registries in the JAK‐pot collaboration.
Zubeyir Salis   +22 more
wiley   +1 more source

Inferring rheumatoid arthritis disease activity status from the electronic health records across health systems

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Disease activity plays a central role in rheumatoid arthritis (RA) clinical studies. The inconsistent availability of data on disease activity in real‐world electronic health records (EHR) data has limited the ability to generate real‐world evidence (RWE). This study aimed to develop and validate scalable machine learning (ML) models to infer
David Cheng   +34 more
wiley   +1 more source

Home - About - Disclaimer - Privacy